HPTN 083 clinical trial
The HPTN 083 clinical trial are prove to have that a pre-exposure prophylaxis (PrEP) regime containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men. Both cabotegravir and oral tenofovir/emtricitabine (TDF/FTC) shown to have high efficacy for pre-exposure prophylaxis (PrEP)
Mas info: https://www.hptn.org/